Kim Hyang, Cable Greg
a Biostatistics , PAREXEL International , Billerica , MA , USA.
J Biopharm Stat. 2018;28(2):350-361. doi: 10.1080/10543406.2017.1402783. Epub 2017 Dec 4.
Assessing treatment effectiveness in longitudinal data can be complex when treatments are not randomly assigned and patients are allowed to switch treatment to other or no treatment, often in a manner that is driven by changes in one or more variables associated with patient or clinical characteristics. There can be confounding of the treatment effect from a time-varying variable, i.e., one which is affected by previous exposure and can in turn also influence subsequent treatment changes. Precision medicine relies on validated biomarkers to better classify patients by their probable response to treatment. However, biomarkers may be a source of time-varying confounding, which are affected by prior treatment in the evaluation and are also subject to measurement errors. The impact of switching medications based on a biomarker has received less attention. We conducted simulation studies to explore biased estimation under various scenarios when marginal structural model estimations are employed. Holding model misspecification issues constant, bias is severe in the presence of multiple switching, along with measurement error and missing data in the covariates.
当治疗不是随机分配的,且允许患者切换到其他治疗或不接受治疗时,评估纵向数据中的治疗效果可能会很复杂,患者切换治疗的方式通常由与患者或临床特征相关的一个或多个变量的变化驱动。治疗效果可能会受到随时间变化的变量的混杂影响,即一个受先前暴露影响且反过来又会影响后续治疗变化的变量。精准医学依靠经过验证的生物标志物,根据患者对治疗的可能反应更好地对患者进行分类。然而,生物标志物可能是随时间变化的混杂因素的一个来源,在评估中受先前治疗的影响,并且也存在测量误差。基于生物标志物切换药物的影响受到的关注较少。我们进行了模拟研究,以探索在采用边际结构模型估计的各种情况下的有偏估计。在模型误设问题不变的情况下,在存在多次切换以及协变量中的测量误差和缺失数据时,偏差会很严重。